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The Successful Cycle of Evidence, Guidelines, and Implementation
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That statins should be prescribed for patients before hospital discharge after an episode of acute coronary syn-
drome (ACS) is a Level of Evidence: 1A recommendation of the American College of Cardiology/American Heart
Association Joint Task Force. This level of recommendation is based upon 2 clinical trials: the MIRACL (Myocar-
dial Ischemia Reduction with Aggressive Cholesterol Lowering) and PROVE-IT (Pravastatin or Atorvastatin Evalua-
tion and Infection Therapy) trials. In the MIRACL trial, 3,086 patients with unstable angina or non–Q-wave myo-
cardial infarction were randomized within 4 days of the event to atorvastatin 80 mg/day or to placebo and
followed for 16 weeks. The primary composite end point occurred in 14.8% of atorvastatin patients and 17.4%
of placebo patients, a 16% relative risk reduction (p  0.048). In the PROVE-IT trial, 4,162 patients hospitalized
with an ACS within the preceding 10 days were randomized to atorvastatin 80 mg/day or pravastatin 40 mg/
day and were followed for a mean of 24 months. The primary event rate was 22.4% in the atorvastatin group
and 26.3% in the pravastatin group, a 16% relative risk reduction (p  0.005). A strong trend toward a reduc-
tion in total mortality was seen in the atorvastatin group (2.2% vs. 3.2%, p  0.07). Using a composite end point
of death, myocardial infarction, and rehospitalization for ACS, the difference between the treatment groups is
already statistically significant at 30 days and remains so throughout the follow-up period. Comprehensive treat-
ment programs in ACS patients that include initiation of statins before hospital discharge have been shown to
improve outcomes such as recurrent myocardial infarction and total mortality at 1 year. Guidelines prove their
utility when their implementation improves outcomes across a broad population at risk, such as in this
instance. (J Am Coll Cardiol 2009;54:1434–7) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.062T
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pDelay always breeds danger; and to protract
a great design is often to ruin it.
—Don Quixote, Miguel de Cervantes (1)
uidelines abound. From 1984 to September 2008, the
merican College of Cardiology/American Heart Associa-
ion Joint Task Force issued 53 guidelines including 7,196
ecommendations (2). Of the 16 current guidelines report-
ng levels of evidence, only 11% are classified as Level of
vidence: A; that is, a recommendation based on evidence
rom randomized trials or meta-analyses (2).
In this issue of the Journal, Morrissey et al. (3) criticize
he Level of Evidence: 1A recommendation that statins
hould be prescribed for patients before hospital discharge
fter an episode of acute coronary syndrome (ACS). We
isagree with their conclusions and with their interpretation
f the facts. Their choice, to attack this recommendation
rom among so many easier targets, seems quixotic.
rom the Division of Cardiology, San Francisco General Hospital, San Francisco,
alifornia; and the University of California, San Francisco School of Medicine, San
rancisco, California. Dr. Waters has received honoraria for lectures from Pfizer and
onsulting fees from AstraZeneca, Merck/Schering-Plough, and Pfizer, and unrelated
o this topic, from Anthera, Aegerion Pharmaceuticals, BioSante Pharmaceuticals,w
ortria, InteKrin Therapeutics, and Oxigene.
Manuscript received May 6, 2009, accepted May 11, 2009.he Context
n more than a dozen large randomized controlled clinical
rials involving more than 100,000 patients, statins have
onsistently reduced the risk of cardiovascular events, across
broad spectrum of patients at risk. In 3 trials of patients
ith stable coronary heart disease (CHD), statins reduced
ot only cardiovascular end points but also total mortality
4–6). More aggressive low-density lipoprotein cholesterol
LDL-C) lowering with higher doses of more potent
tatins, compared with lower doses or less potent statins, has
een shown to provide incremental risk reduction in pa-
ients with stable CHD (7,8).
Survivors of ACS will have stable CHD within 6 to 12
onths and will benefit from long-term statin treatment.
orrissey et al. (3) agree that these patients should be
reated long-term, but disagree that treatment should begin
n hospital. The evidence clearly indicates that compliance
ith treatment is higher and long-term outcomes better
hen statins are begun before hospital discharge (9–11).
he Standard
oronary heart disease has evolved dramatically over the
ast 40 years, and clinical trials of CHD have evolved as
ell. From 1966 to 1969 the Coronary Drug Project
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October 6, 2009:1434–7 Statin Therapy in ACSnrolled men ages 30 to 64 years who had suffered a
yocardial infarction (MI) a median of 23 months previ-
usly, and who were New York Heart Association func-
ional class I to II (12). In the placebo group after 6.2 years
f follow-up, 25.9% of the patients had died and 14.7% of
hem had experienced another MI. With high rates of hard
nd point events such as this, clinical trials could be
erformed with reasonable sample sizes and follow-up
eriods. Over the ensuing decades, event rates have fallen
ramatically; for example, in a recent large trial of patients
ith stable CHD followed for 4.9 years, the total mortality
ate was 5.6% and the rate of nonfatal MI was 6.2% in the
ontrol group (7). Event rates in recent trials have even been
ubstantially lower than the rates predicted by the Framing-
am Risk Score (13).
As death and ST-segment elevation MI have become less
ommon, other end points such as non–ST-segment eleva-
ion MI, hospitalization for unstable angina, hospitalization
or heart failure, and coronary revascularization have be-
ome more common. These “softer” events are expensive
nd worsen quality of life. To ignore them is not reasonable.
reatments that reduce these events are clinically useful.
ue to the evolution of CHD, we now accept as a primary
nd point a composite of clinically important events that
epresent the current reality of the disease.
he Evidence
n the MIRACL (Myocardial Ischemia Reduction with
ggressive Cholesterol Lowering) trial, 3,086 patients with
nstable angina or non–Q-wave MI were randomized
ithin 4 days of the event to atorvastatin 80 mg/day or to
lacebo and followed for 16 weeks (14). The primary end
oint, a composite of death, MI, resuscitated cardiac arrest,
nd recurrent symptomatic myocardial ischemia with objec-
ive evidence requiring emergency hospitalization, occurred
n 14.8% of atorvastatin patients and 17.4% of the placebo
atients (hazard ratio [HR]: 0.84, 95% confidence interval
CI]: 0.70 to 1.00, p  0.048).
The statement by Morrissey et al. (3) that “an unplanned
nterim analysis was performed in MIRACL without ad-
ustment of p value in the reported results” is not correct
Elliot Rapaport, Chair, MIRACL Data and Safety Mon-
toring Board, personal communication, May 4, 2009). As
learly stated in the paper (3): “The study protocol specified
interim analyses of safety and efficacy by the data and
afety monitoring board. A significance level of p  0.001
as used for each interim analysis, with a significance level
or the final analysis adjusted to p  0.049 to preserve the
verall type I error rate at p  0.05.”
In the PROVE-IT (Pravastatin or Atorvastatin with
ggressive Cholesterol Lowering) trial, 4,162 patients hos-
italized with an ACS within the preceding 10 days were
andomized to atorvastatin 80 mg/day or pravastatin 40
g/day and were followed for a mean of 24 months (15).
he primary end point consisted of death, MI, documented tnstable angina requiring rehos-
italization, stroke, and revascu-
arization (at least 30 days after
andomization). The primary
vent rate was 22.4% in the ator-
astatin group and 26.3% in the
ravastatin group (HR: 0.84,
5% CI: 0.74 to 0.95, p 
.005). A strong trend toward a
eduction in total mortality was
een in the atorvastatin group
2.2% vs. 3.2%, p  0.07).
The results of the PROVE-IT trial are particularly
oteworthy because the comparator group was treated with
ravastatin 40 mg/day, the drug and dose that significantly
educed the primary end point in 4 older large randomized
lacebo-controlled trials.
ime to Benefit
linical trials are not designed to demonstrate when the
enefit of treatment begins. However, as shown in Figure 1,
he cumulative hazard ratios for the primary end point in the
ROVE-IT trial are reduced by approximately the same
mount from 15 days to 4 months, with the difference
ecoming statistically significant at the later point (16).
sing a composite end point of death, MI, and rehospital-
zation for ACS, the difference between the treatment
roups is already statistically significant at 30 days and
emains so throughout the follow-up period (16). Clearly,
arly initiation of treatment provides near immediate
enefit.
elationship Between Benefit and LDL-C Levels
n the MIRACL trial, patients with a baseline LDL-C
elow the median value of 121 mg/dl benefited from
torvastatin (HR: 0.77, 95% CI: 0.59 to 0.98), and baseline
DL-C was not a predictor of events (14,17). In the
ROVE-IT trial, benefit appeared to be greater among
atients with a baseline LDL-C level 125 mg/dl, where a
4% event reduction was seen, compared with only 7%
mong patients with lower LDL-C levels (15). This dis-
arity between the MIRACL and PROVE-IT trials may be
ue to the different durations of follow-up in the trials, or to
he fact that 25% of PROVE-IT patients were on pre-
xisting statin therapy at baseline.
In the TNT (Treating to New Targets) trial, LDL-C
evels on treatment were a strong predictor of events, with
ower event rates seen at the lowest attained LDL-C levels
18). Lower achieved LDL-C levels were also associated
ith reduced risk in the PROVE-IT trial: patients with
DL-C levels 40 mg/dl had a relative risk of 0.61 (95%
I: 0.40 to 0.91) compared with patients with an on-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CHD  coronary heart
disease
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarctionreatment LDL-C of 80 to 100 mg/dl (19).
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Statin Therapy in ACS October 6, 2009:1434–7dverse Effects of High-Dose Statins
s pointed out by Morrissey et al. (3), the 80-mg dose of
imvastatin was associated with a much higher incidence of
yopathy than the 20-mg dose in both the A to Z
Aggrastat to Zocor) (20) and SEARCH (Study of the
ffectiveness of Additional Reductions in Cholesterol and
omocysteine) (21) trials. On the other hand, as shown in
able 1, the 80-mg dose of atorvastatin has been given to
8,696 patients in clinical trials, usually for between 4 and 5
ears, with an overall incidence of hepatic enzyme elevation
f 1.43%, and only 4 patients with creatine kinase elevations
10 times the upper limit of normal. The incidence of
dverse effects is likely to be higher in patients not partici-
ating in a clinical trial; nevertheless, these data indicate
hat 80 mg of atorvastatin is probably safer than 81 mg of
spirin.
mplementation
omprehensive treatment programs in ACS patients that
nclude initiation of statins before hospital discharge have
een shown to improve outcomes. In the CHAMP (Car-
afety of Atorvastatin 80 mg in Clinical TrialsTable 1 Safety of Atorvastatin 80 mg in Clinical Trials
Study Follow-Up Patients
ALT/AST
>3 ULN
CK
>10 ULN
Newman et al.* Variable 4,798 26 (0.6%) 2 (0.06%)
PROVE-IT (15) 2 yrs 2,099 69 (3.3%) NA
TNT (7) 4.9 yrs 4,995 60 (1.2%) 0
IDEAL (8) 4.8 yrs 4,439 61 (1.38%) 0
SPARCL† 4.9 yrs 2,365 51 (2.2%) 2 (0.08%)
Total Variable 18,696 267 (1.43%) 4 (0.024%)
Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80mg versus 10
g derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2005;97:61–7.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
igh-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59.
Figure 1 HRs and 95% CIs at Various Time Points Throughout
The primary end point is a composite of death, myocardial infarction, unstable ang
ple composite end point is death, myocardial infarction, or rehospitalization with a
40 mg is already statistically significant for the triple composite end point by 30 d
et al. (16). CI  confidence interval; HR  hazard ratio.ALT alanine aminotransferase; AST aspartate aminotransferase; CK creatine kinase; ULN
upper limit of normal.iac Hospitalization Atherosclerosis Management Pro-
ram) trial (9), the proportion of ACS patients who received
statin at hospital discharge increased from 6% to 86% and
he proportion achieving an LDL-C of 100 mg/dl in-
reased from 6% to 58%. This was associated with a
eduction in recurrent MI and total mortality at 1 year. A
uidelines-based program that included lipid-lowering
rugs also improved outcomes in the ACC GAP (American
ollege of Cardiology Guidelines Applied in Practice)
roject (10). Statins at hospital discharge improve outcomes
ven in ACS patients with LDL-C levels 100 mg/dl (11).
Guidelines prove their utility when their implementation
mproves outcomes across a broad population at risk.
The proof of the pudding is in the eating.
—Don Quixote, Miguel de Cervantes (22)
eprint requests and correspondence: Dr. David D. Waters,
ivision of Cardiology, Room 5G1, San Francisco General
ospital, 1001 Potrero Avenue, San Francisco, California 94114.
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